Rohit Bhatheja, MD
Cardiovascular Disease · Orlando, FLNPI 1912097627
Payments from drug & device makers
Across 551 payments — averaging $1626.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$407K
- Amgen$90K
- Abbott$81K
- Penumbra, Inc.$80K
- Novartis$74K
- Boehringer Ingelheim$57K
- plus $107K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 106 | $406,771 |
| Amgen | 32 | $89,942 |
| Abbott | 81 | $81,207 |
| Penumbra, Inc. | 76 | $80,261 |
| Novartis | 31 | $73,627 |
| Boehringer Ingelheim | 55 | $57,438 |
| Boston Scientific | 50 | $30,173 |
| Chiesi USA, Inc. | 18 | $27,361 |
| EKOS Corporation | 5 | $15,050 |
| Philips North America LLC | 6 | $9,239 |
| Janssen Research & Development, LLC | 4 | $6,838 |
| Lilly USA, LLC | 7 | $6,484 |
| Cvrx, Inc. | 11 | $4,628 |
| Terumo Medical Corporation | 2 | $2,886 |
| Medtronic | 15 | $1,998 |
| Shockwave Medical, Inc | 5 | $431 |
| Abiomed | 3 | $421 |
| Siemens Medical Solutions USA, Inc. | 1 | $175 |
| Merck | 8 | $171 |
| Novo Nordisk | 4 | $166 |
| Edwards Lifesciences | 1 | $145 |
| E.r. Squibb & Sons, L.L.C. | 6 | $122 |
| Biotronik Inc. | 1 | $90 |
| Esperion Therapeutics, Inc. | 4 | $81 |
| Livanova USA, Inc. | 1 | $80 |
| Pfizer | 3 | $62 |
| AstraZeneca | 2 | $57 |
| Bayer | 3 | $50 |
| Myocardial Solutions, Inc. | 1 | $48 |
| Actelion Pharmaceuticals US, Inc. | 2 | $46 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $43 |
| Stryker | 1 | $32 |
| Kestra Medical Technology Services, Inc. | 1 | $29 |
| Angiodynamics, Inc. | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
How this compares
$896,190 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Orlando
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
- Ferris GeorgeSt Augustine$3.8M
- Duccio BaldariWellington$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.